Developing Treatment for SCN2A

SCN2A Australia
November 23, 2019
Webinar
0 Comments

Prof Steven Petrou and Dr Kiran Reddy discuss the RC-222 program developing an ASO treatment for gain-of-function SCN2A epilepsies.

Facebook Posts

SCN2A Australia

13 hours ago

Lots of great presentations coming from the American Epilepsy Society.

Below is an interesting poster from Spain presented at #AES2019 showing that adults with intellectual disability and epilepsy were unlikely to have had genetic testing, or other testing done, particularly if they were institutionalised. Shows that there is a long way to go in understanding what severe developmental and epileptic encephalopathies look like later in life.

#SCN2A #CureSCN2A ... See MoreSee Less

Photo

View on Facebook

SCN2A Australia

1 day ago

From XENON PHARMACEUTICALS
AES PRESENTATIONS AND ANNOUNCEMENTS:

Click on link to read about the programs. ... See MoreSee Less

Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting | Xenon Pharmaceuticals Inc.

investor.xenon-pharma.com

The Investor Relations website contains information about Xenon Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts.

View on Facebook